Creator sentiment
100/100
● Bullish 100%● Neutral 0%● Bearish 0%
1 creators · 1 views · past 7 days
Updated October 20, 2026
The bull case
- +Revenue has more than doubled in just a couple of years, driven by weight-loss treatments and the new pill version gaining adoption.
- +Operating margin has nearly doubled since 2017 to 49.7%, and gross margins are above 80%, showing strong pricing power.
- +Return on invested capital has been above 15% since 2020 and recently reached 37.7%, nearly four times its weighted average cost of capital.
- +The stock trades at 26x forward earnings, which he sees as attractive for a business with these characteristics, and his discounted valuation suggests fair value of $1,523 per share, over 20% upside.
The bear case
Nothing notable in the past 7 days.
What StockTubers recently said
Parkev Tatevosian, CFA BullishOct 20Target $1,523
📹 Here's What I'm Planning With My Eli Lilly Position
Revenue has more than doubled in just a couple of years, driven by weight-loss treatments and the new pill version gaining adoption. · Operating margin has nearly doubled since 2017 to 49.7%, and gross margins are above 80%, showing strong pricing power. · Return on invested capital has been above 15% since 2020 and recently reached 37.7%, nearly four times its weighted average cost of capital. · The stock trades at 26x forward earnings, which he sees as attractive for a business with these characteristics, and his discounted valuation suggests fair value of $1,523 per share, over 20% upside.